Business Wire·Mar 5, 2026, 6:30 AM ET

Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress

ZURA

Zura Bio Limited announced its Phase 2 TibuSURE trial design for tibulizumab in systemic sclerosis will be presented as a poster at the Systemic Sclerosis World Congress in Athens, Greece, from March 5–7, 2026.
The poster presentation (Abstract ID 184; Poster P.267) outlines the study rationale & design but will not include any clinical efficacy or safety data.
TibuSURE is the first trial evaluating dual inhibition of interleukin-17A (IL-17A) & B-cell activating factor (BAFF) in diffuse cutaneous systemic sclerosis using tibulizumab, a bispecific antibody.
The global Phase 2 study plans to enroll approximately 80 adults randomized 1:1 to receive tibulizumab or placebo every four weeks for 24 weeks, followed by a 28-week open-label extension.
The primary endpoint is the change from baseline in modified Rodnan Skin Score at Week 24, with topline results anticipated in the first half of 2027.
Christopher Denton, M.D., Ph.D., from University College London, will present the poster during sessions on Friday, March 6, or Saturday, March 7, 2026.
Tibulizumab is an investigational tetravalent dual-antagonist antibody engineered to neutralize IL-17A & BAFF, currently being evaluated in Phase 2 studies for systemic sclerosis (TibuSURE) & hidradenitis suppurativa (TibuSHIELD).
Zura Bio Limited is a clinical-stage biotechnology company developing novel dual-pathway antibodies for autoimmune diseases, with additional candidates crebankitug (ZB-168) & torudokimab (ZB-880) having completed Phase 1/1b studies.
Tibulizumab remains an investigational compound that has not received marketing approval from the U.S. Food & Drug Administration or any other regulatory authority.